Accretion Nutraveda Limited (BOM:544694)
India · Delayed Price · Currency is INR 273.25
0.00 (0.00%)
At close: Oct 23, 2026
Accretion Nutraveda Revenue
In the fiscal year ending March 31, 2026, Accretion Nutraveda had annual revenue of 336.15M INR with 110.07% growth. Accretion Nutraveda had revenue of 97.75M in the quarter ending March 31, 2026, a decrease of -9.93%. That makes Accretion Nutraveda the 40,981st largest company in the world by revenue and 4,014th in India.
Revenue
336.15M
Revenue Growth
+110.07%
P/S Ratio
5.89
Revenue / Employee
n/a
Employees
n/a
Market Cap
1.98B
Revenue by Geography
- India 334.84M 99.6%
- Export 1.20M 0.4%
Fiscal year ended Mar 31, 2026 See the full Accretion Nutraveda breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 336.15M | 176.13M | 110.07% |
| Mar 31, 2025 | 160.02M | 109.33M | 215.69% |
| Mar 31, 2024 | 50.69M | 20.66M | 68.81% |
| Mar 31, 2023 | 30.03M | 24.18M | 413.23% |
| Mar 31, 2022 | 5.85M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Aarey Drugs & Pharmaceuticals | 4.15B |
| Influx Healthtech | 1.47B |
| Smruthi Organics | 1.12B |
| Kimia Biosciences | 1.12B |
| Panchsheel Organics | 1.08B |
| Resonance Specialties | 1.02B |
| Shree Ganesh Remedies | 989.78M |
| Tyche Industries | 500.33M |